Purpose: Integrins are critical to cancer progression. Integrin alpha 5 (ITGA5) is correlated with the prognosis of cervical cancer patients. However, whether ITGA5 plays an active role in cervical cancer progression or not remains unknown.
Methods: ITGA5 protein expression was detected in 155 human cervical cancer tissues by immunohistochemistry. Data from The Cancer Genome Atlas were utilized to identify risk factors for the overall survival of cervical cancer patients and ITGA5-associated differentially expressed genes. Analyses of single-cell RNA-seq based on Gene Expression Omnibus datasets were performed to show the coexpression of ITGA5 and angiogenesis factors. Tube formation assay, 3D spheroid sprout assay, qRT-PCR, Western Blotting, ELISA, and immunofluorescence were conducted to explore the angiogenic function of ITGA5 in vitro and underlying mechanisms.
Results: High ITGA5 level was significantly correlated with increased risk in terms of overall survival and advanced disease stage in cervical cancer patients. ITGA5-associated differentially expressed genes linked ITGA5 to angiogenesis, and immunohistochemistry showed a positive correlation between ITGA5 and microvascular density in cervical cancer tissues. Moreover, tumor cells transfected with ITGA5-targeting siRNA decreased ability to promote endothelial tube formation in vitro. ITGA5/VEGFA coexpression was observed in a tumor cell subpopulation and the decreased endothelial angiogenesis by downregulating ITGA5 could be reversed by VEGFA. Bioinformatics analysis highlighted the PI3K-Akt signaling pathway as downstream of ITGA5. Downregulation of ITGA5 in tumor cells significantly decreased p-AKT and VEGFA levels. Fibronectin (FN1) coated cells or transfected with FN1-targeting siRNA showed fibronectin may play a critical role on ITGA5-mediated angiogenesis.
Conclusion: ITGA5 promotes angiogenesis and possibly be a potential predictive biomarker for poor survival of patients in cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242342 | PMC |
| http://dx.doi.org/10.1002/cam4.5873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Absence of EpCAM in cervical cancer cells is involved in slug induced epithelial-mesenchymal transition.
Cancer Cell Int
March 2025
Department of Reproductive Medicine, The First Affiliated Hospital of the Medical College, Xi'an Jiaotong University, 76 West Yanta Road, Shaanxi Province, Xi'an, 710061, People's Republic of China.
Tumor-Infiltrating Lymphocyte Therapy: A New Frontier.
Transplant Cell Ther
March 2025
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address:
In recent years, the successful use of tumor-infiltrating lymphocyte (TIL) therapy to treat melanoma not only culminated in a landmark Food and Drug Administration approval, but has also fueled the emergence of a new, rapidly growing field in TIL cellular immunotherapy surrounding novel enhancements in TIL design, refined manufacturing strategies to enrich for more potent TIL populations, as well as numerous clinical trials now investigating TIL therapy in additional solid tumor types beyond melanoma. This review provides a summary of the latest advances in TIL therapy and what lies ahead for the field. The first section explores several solid cancers that demonstrate the greatest potential for future indications of TIL therapy.
View Article and Find Full Text PDFCervical cancer in pregnancy.
Semin Perinatol
March 2025
Lab of Gynecological Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, UZ Leuven, Leuven, Belgium; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:
Cervical cancer is one of the most common and challenging malignancies diagnosed during pregnancy, requiring a complex balance between effective oncological management and pregnancy preservation. This narrative review synthesizes current evidence and clinical experience regarding the management of cervical cancer in pregnant patients. While treatment should generally follow standard protocols for nonpregnant patients, emerging data suggest that pregnancy can often be safely maintained without compromising oncological outcomes.
View Article and Find Full Text PDFSpatial analysis of HPV infection and contextual factors associated with higher HPV prevalence.
Ann Epidemiol
March 2025
NOVA National School of Public Health, NOVA University Lisbon, Av. Padre Cruz, 1600-560, Lisbon, Portugal; NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, NOVA University Lisbon, Av. Padre Cruz, 1600-560, Lisbon, Portugal; Public Health Department, Central Region Health Administration, Av. Dom Afonso Henriques, 141, 3001-553, Coimbra, Portugal; National Institute of Health, Doutor Ricardo Jorge, Av. Padre Cruz, 11, 1649-016, Lisboa, Portugal.
Objectives: To identify areas with high rates of high-risk Papillomavirus (hrHPV) infection and associated contextual factors in the Centre Region of Portugal at the municipality level.
Study Design: We conducted an ecological study in 78 municipalities located in the Central Region of Portugal from March 2019 to December 2022.
Methods: We used data from the cervical cancer screening (CCS) program database after switching to primary HPV testing.
Long Term Results of a Phase II Study of Adjuvant Proton Radiotherapy for Node-Positive Cancer of the Uterus and Cervix: Proton Radiation for Uterine/Cervical Cancer.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Purpose/objective(s): Patients with node-positive (LN+) uterine or cervical cancer often require post-operative radiation (RT) to the pelvis and para-aortic nodes. A prospective phase II study was conducted to evaluate the efficacy of proton beam RT for LN+ uterine or cervical cancer.
Materials/methods: Patients with IIIC uterine and cervical cancer post hysterectomy and lymphadenectomy were eligible.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!